Oramed Pharmaceuticals Inc. (ORMP.TA)
ILA 846.0
(2.3%)
ILA 846.0
(2.3%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | -142.86 Million USD | -92.35% |
| 2021 | -74.27 Million USD | -88.48% |
| 2020 | -39.4 Million USD | 23.72% |
| 2019 | -51.65 Million USD | -6.1% |
| 2018 | -48.68 Million USD | -26.03% |
| 2017 | -38.63 Million USD | -2.02% |
| 2016 | -37.86 Million USD | -29.5% |
| 2015 | -29.23 Million USD | -38.67% |
| 2014 | -21.08 Million USD | -35.29% |
| 2013 | -15.58 Million USD | -34.63% |
| 2012 | -11.57 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q3 | -11.05 Million USD | 21.51% |
| 2023 Q1 | -18.77 Million USD | 45.23% |
| 2023 Q2 | -14.08 Million USD | 24.99% |
| 2022 Q3 | -29.18 Million USD | 26.9% |
| 2022 FY | -142.86 Million USD | -92.35% |
| 2022 Q1 | -35.99 Million USD | 37.1% |
| 2022 Q2 | -39.91 Million USD | -10.9% |
| 2022 Q4 | -34.27 Million USD | -17.45% |
| 2021 Q3 | -23.73 Million USD | -43.91% |
| 2021 Q4 | -57.22 Million USD | -141.04% |
| 2021 Q1 | -16.12 Million USD | 16.26% |
| 2021 Q2 | -16.49 Million ILA | -2.29% |
| 2021 FY | -74.27 Million USD | -88.48% |
| 2020 Q3 | -10.11 Million USD | -26.73% |
| 2020 Q2 | -7.98 Million USD | 43.01% |
| 2020 Q4 | -19.25 Million USD | -90.31% |
| 2020 Q1 | -14.01 Million USD | -65.96% |
| 2020 FY | -39.4 Million USD | 23.72% |
| 2019 Q1 | -12.93 Million USD | 25.04% |
| 2019 Q2 | -14.78 Million USD | -14.33% |
| 2019 FY | -51.65 Million USD | -6.1% |
| 2019 Q4 | -8.44 Million USD | -1.87% |
| 2019 Q3 | -8.28 Million USD | 43.94% |
| 2018 Q4 | -17.25 Million USD | -51.91% |
| 2018 Q1 | -10.81 Million USD | -13.33% |
| 2018 Q3 | -11.35 Million USD | 29.74% |
| 2018 Q2 | -16.16 Million USD | -49.4% |
| 2018 FY | -48.68 Million USD | -26.03% |
| 2017 Q2 | -7.62 Million USD | 37.74% |
| 2017 Q4 | -9.54 Million USD | 6.63% |
| 2017 FY | -38.63 Million USD | -2.02% |
| 2017 Q1 | -12.25 Million USD | -33.36% |
| 2017 Q3 | -10.22 Million USD | -34.05% |
| 2016 Q3 | -13.36 Million USD | -64.35% |
| 2016 FY | -37.86 Million USD | -29.5% |
| 2016 Q4 | -9.18 Million USD | 31.27% |
| 2016 Q2 | -8.13 Million USD | -8.83% |
| 2016 Q1 | -7.47 Million USD | 21.21% |
| 2015 Q2 | -6.32 Million USD | 5.1% |
| 2015 Q1 | -6.66 Million USD | 10.03% |
| 2015 FY | -29.23 Million USD | -38.67% |
| 2015 Q4 | -9.48 Million USD | -11.01% |
| 2015 Q3 | -8.54 Million USD | -35.01% |
| 2014 Q2 | -6.6 Million USD | -59.78% |
| 2014 Q1 | -4.13 Million USD | -0.47% |
| 2014 Q3 | -5.88 Million USD | 10.9% |
| 2014 Q4 | -7.41 Million USD | -25.89% |
| 2014 FY | -21.08 Million USD | -35.29% |
| 2013 FY | -15.58 Million USD | -34.63% |
| 2013 Q1 | -4.67 Million USD | -67.61% |
| 2013 Q3 | -3.54 Million USD | 28.13% |
| 2013 Q4 | -4.11 Million USD | -16.27% |
| 2013 Q2 | -4.92 Million USD | -5.34% |
| 2012 Q3 | -3.76 Million USD | 0.0% |
| 2012 Q4 | -2.78 Million USD | 25.85% |
| 2012 FY | -11.57 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|